ProAxsis launches first-in-class ProteaseTag™ test for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

Date : August 11, 2015


ProAxsis, has officially launched its proprietary first-in-class ProteaseTag™ immunoassay kits to research labs and announces its first customer orders, including a major pharma company.

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. This test measures Neutrophil Elastase, a leading indicator of infection in patients with Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) and an important drug target. The rapid and easy-to-use tests incorporate patented ProteaseTags™; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags™ provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.

ProAxsis is part of the NetScientific group of technology companies and is one of the group’s core portfolio companies.

David Gough, Chairman of ProAxsis, and Executive Director of NetScientific, said: “The launch of the first ProteaseTag™ immunoassay is a major milestone for ProAxsis, allowing it to access the global protease therapeutic market currently worth $7.2 billion, and expected to double in size by 2020. We believe there is a huge potential demand for this unique test that could significantly contribute to respiratory disease and infection research. ProteaseTags™ also have the benefit of being applicable to a wide pipeline of products targeting other indications, such as cancer and cardiovascular disorders.”

Dr Lorraine Martin, CEO of ProAxsis, said: “Our technology’s competitive advantages include higher sensitivity and specificity in measuring active proteases in clinical samples than existing methods, which is resonating with customers. Receiving our first orders from two notable companies is a huge step forward for us and we expect a good conversion of our current pipeline.”

ProAxsis is also developing a point-of-care (PoC) NEATstik™ test to measure active proteases in CF and COPD which will enable the proactive management of these diseases with the aim of improving patient outcome and reducing hospitalisations. NEATstik™ will enable entry into the rapidly growing PoC market that is estimated to be worth over £20 billion. The test has the potential to revolutionise the management of respiratory diseases, acting as an early monitoring device for patients to alert them of a potential infection.